+

WO2003047513A3 - Methode de traitement de l'hypertension oculaire - Google Patents

Methode de traitement de l'hypertension oculaire Download PDF

Info

Publication number
WO2003047513A3
WO2003047513A3 PCT/US2002/038040 US0238040W WO03047513A3 WO 2003047513 A3 WO2003047513 A3 WO 2003047513A3 US 0238040 W US0238040 W US 0238040W WO 03047513 A3 WO03047513 A3 WO 03047513A3
Authority
WO
WIPO (PCT)
Prior art keywords
ocular hypertension
treating ocular
eye
relates
prostaglandin
Prior art date
Application number
PCT/US2002/038040
Other languages
English (en)
Other versions
WO2003047513A2 (fr
Inventor
Miller J Ogidigben
Robert N Young
Kathleen M Metters
Deborah M Slipetz
Xavier Billot
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Miller J Ogidigben
Robert N Young
Kathleen M Metters
Deborah M Slipetz
Xavier Billot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Merck Frosst Canada Inc, Miller J Ogidigben, Robert N Young, Kathleen M Metters, Deborah M Slipetz, Xavier Billot filed Critical Merck & Co Inc
Priority to CA002466757A priority Critical patent/CA2466757A1/fr
Priority to AU2002346562A priority patent/AU2002346562A1/en
Priority to EP02784630A priority patent/EP1461026A2/fr
Priority to JP2003548774A priority patent/JP2005514378A/ja
Priority to US10/494,775 priority patent/US20040254230A1/en
Publication of WO2003047513A2 publication Critical patent/WO2003047513A2/fr
Publication of WO2003047513A3 publication Critical patent/WO2003047513A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des agonistes sélectifs puissants du sous-type EP4 de récepteurs de la prostaglandine E2, l'utilisation de ceux-ci ou une formulation de ceux-ci dans le traitement du glaucome et d'autres états relatifs à une pression intraoculaire élevée dans l'oeil d'un patient. L'invention concerne également l'utilisation de tels composés permettant de conférer un effet neuroprotecteur à l'oeil d'espèces mammifères, notamment les êtres humains.
PCT/US2002/038040 2001-12-03 2002-11-27 Methode de traitement de l'hypertension oculaire WO2003047513A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002466757A CA2466757A1 (fr) 2001-12-03 2002-11-27 Methode de traitement de l'hypertension oculaire
AU2002346562A AU2002346562A1 (en) 2001-12-03 2002-11-27 Method for treating ocular hypertension
EP02784630A EP1461026A2 (fr) 2001-12-03 2002-11-27 Methode de traitement de l'hypertension oculaire
JP2003548774A JP2005514378A (ja) 2001-12-03 2002-11-27 高眼圧症の治療方法
US10/494,775 US20040254230A1 (en) 2001-12-03 2002-11-27 Method for treating ocular hypertension

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33811701P 2001-12-03 2001-12-03
US60/338,117 2001-12-03
US40050402P 2002-08-02 2002-08-02
US60/400,504 2002-08-02

Publications (2)

Publication Number Publication Date
WO2003047513A2 WO2003047513A2 (fr) 2003-06-12
WO2003047513A3 true WO2003047513A3 (fr) 2004-07-15

Family

ID=26991044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038040 WO2003047513A2 (fr) 2001-12-03 2002-11-27 Methode de traitement de l'hypertension oculaire

Country Status (5)

Country Link
EP (1) EP1461026A2 (fr)
JP (1) JP2005514378A (fr)
AU (1) AU2002346562A1 (fr)
CA (1) CA2466757A1 (fr)
WO (1) WO2003047513A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900622B1 (en) 2004-04-30 2014-12-02 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8999397B2 (en) 2004-04-30 2015-04-07 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9101583B2 (en) 2004-04-30 2015-08-11 Allergan, Inc. Microparticles manufactured in an oil-in-water process comprising a prostamide

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US7872045B2 (en) 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
WO2003047513A2 (fr) * 2001-12-03 2003-06-12 Merck & Co., Inc. Methode de traitement de l'hypertension oculaire
WO2003074483A1 (fr) * 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP4582456B2 (ja) * 2003-01-21 2010-11-17 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体およびその医薬用途
US7235586B2 (en) 2003-09-09 2007-06-26 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
DK1761495T3 (da) 2004-06-04 2012-06-18 Allergan Inc Piperidinylprostaglandinanaloge som midler til nedsættelse af øjets indre tryk
US7101906B2 (en) * 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US8013159B2 (en) 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
WO2008058766A1 (fr) 2006-11-16 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Agonistes ep2 et ep4 en tant qu'agents destinés au traitement d'une infection virale de l'influenza a
EP2149554A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamides en tant que modulateurs du récepteur EP2
EP2149551A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2
EP2149552A1 (fr) 2008-07-30 2010-02-03 Bayer Schering Pharma AG Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2
CA2777384A1 (fr) 2009-10-14 2011-04-21 Gemmus Pharma, Inc. Traitement par polytherapie pour infections virales
AU2013292357C1 (en) 2012-07-19 2017-05-25 Cayman Chemical Company, Inc. Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated disease and conditions
AU2014229065B2 (en) 2013-03-15 2017-03-09 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
BR112015023080A2 (pt) 2013-03-15 2017-07-18 Cayman Chemical Co Inc composto, composição farmacêutica, e, método para tratamento de doenças
WO2014144610A1 (fr) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Composés lactames en tant qu'agonistes sélectifs du récepteur ep4 pour l'utilisation dans le traitement de maladies et d'états à médiation par ep4
AU2014290512A1 (en) 2013-07-19 2015-11-12 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
EP3030252B1 (fr) 2013-08-09 2018-11-07 Ardelyx, Inc. Composés et procédés d'inhibition du transport de phosphate
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
WO2003047513A2 (fr) * 2001-12-03 2003-06-12 Merck & Co., Inc. Methode de traitement de l'hypertension oculaire
US20030176479A1 (en) * 2002-03-18 2003-09-18 Cameron Kimberly O. Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047513A2 (fr) * 2001-12-03 2003-06-12 Merck & Co., Inc. Methode de traitement de l'hypertension oculaire
US20030176479A1 (en) * 2002-03-18 2003-09-18 Cameron Kimberly O. Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] XP002978749, accession no. STN Database accession no. 139:30848 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900622B1 (en) 2004-04-30 2014-12-02 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8911767B2 (en) 2004-04-30 2014-12-16 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8999397B2 (en) 2004-04-30 2015-04-07 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9101583B2 (en) 2004-04-30 2015-08-11 Allergan, Inc. Microparticles manufactured in an oil-in-water process comprising a prostamide
US9326949B2 (en) 2004-04-30 2016-05-03 Allergan, Inc. Method of making oil-in-oil emulsified polymeric implants containing a hypotensive lipid
US9393223B2 (en) 2004-04-30 2016-07-19 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems

Also Published As

Publication number Publication date
AU2002346562A1 (en) 2003-06-17
EP1461026A2 (fr) 2004-09-29
JP2005514378A (ja) 2005-05-19
CA2466757A1 (fr) 2003-06-12
WO2003047513A2 (fr) 2003-06-12

Similar Documents

Publication Publication Date Title
WO2003047513A3 (fr) Methode de traitement de l'hypertension oculaire
WO2005002520A3 (fr) Compositions ophtalmiques destinees au traitement d'hypertension oculaire
WO2007108968A3 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
WO2007076360A8 (fr) (indazol-5-yl)-pyrazines et (1,3-dihydro-indol-2-un)- pyrazines pour le traitement de maladies et de conditions a mediation de rho kinase
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
WO2003092584A3 (fr) Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques
PL373863A1 (en) Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
DK1553953T3 (da) Fremgangsmåde og præparat omfattende latanoprost til behandling af okulær hypertension og glaucom
ATE487514T1 (de) 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
WO2004066979A3 (fr) Dispositif et procede a liberation prolongee pour l'administration oculaire d'agents adrenergiques
CA2505086A1 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
WO2002098350A3 (fr) Pyranoindazoles et leur utilisation dans le traitement du glaucome
WO2005020917A3 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
WO2004043354A3 (fr) Compositions ophtalmiques pour traiter l'hypertension oculaire
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
WO2003047417A3 (fr) Agoniste du recepteur ep4, compositions et procedes associes
WO2004037786A3 (fr) Agonistes des recepteurs ep4
WO2006044425A3 (fr) Compositions ophtalmiques de traitement de l'hypertension oculaire
EP1251862A4 (fr) Compositions ophthalmiques pour traiter l'hypertension oculaire
WO2007146136A3 (fr) Compositions ophtalmiques pour traiter une hypertension oculaire
BR0017158A (pt) Agonistas de 5ht2 para controlar a iop e tratar o glaucoma
WO2007127711A3 (fr) Cannabidiols anormaux utiles comme agents destinés à faire baisser la pression intraoculaire
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
WO2003105724A3 (fr) Nouveaux bloqueurs de canaux maxi k, methodes d'utilisation et procedes de fabrication associes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10494775

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002346562

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2466757

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002784630

Country of ref document: EP

Ref document number: 2003548774

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002784630

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2002784630

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载